SCHEMBL133918

SCHEMBL133918

CSC(=NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.33
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
DGAT1 O75907 1/20 0.31
MIF P14174 1/20 0.30
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7865780 1.00 KMT2A (0.33) KMT2ANFKB1NFKB2RELATDP1
SCHEMBL206812 1.00 KMT2A (0.33) KMT2ANFKB1NFKB2RELATDP1
Sulfuric Acid SCHEMBL28494040 0.94 CA12 (0.33) KMT2ATDP1MAOAMAOBCA1
SCHEMBL2342887 0.86 KMT2A (0.33) KMT2ANFKB1NFKB2RELATDP1
SCHEMBL21359614 0.86 DGAT1 (0.31) DGAT1
SCHEMBL2823978 0.86 KMT2A (0.33) KMT2ANFKB1NFKB2RELATDP1
SCHEMBL2342888 0.86 KMT2A (0.33) KMT2ANFKB1NFKB2RELATDP1
SCHEMBL21359615 0.86 DGAT1 (0.31) DGAT1
SCHEMBL15177020 0.84 KMT2A (0.33) KMT2ANFKB1NFKB2RELATDP1
SCHEMBL14535778 0.84 APLNR (0.38) KMT2ATDP1CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119162691-B Waterproof antibacterial polyester fiber fabric and preparation method thereof 南通洁万家纺织有限公司 2025-05-13 CN claimed
US-12285501-B2 Compound targeting norepinephrine transporter Higuchi, Takahiro (DE) 2025-04-29 US claimed
CN-119698421-A Process for preparing tetrodotoxin and analogues thereof 北京生命科学研究所 2025-03-25 CN claimed
CN-119371391-A Aroyl compound and preparation method and application thereof 河北医科大学 2025-01-28 CN claimed
CN-119162691-A Waterproof antibacterial polyester fiber fabric and preparation method thereof 南通洁万家纺织有限公司 2024-12-20 CN claimed
WO-2024032799-A1 Preparation Method of Tetrodotoxin and its Analog NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-02-15 WO claimed
CN-113301926-B Compounds targeting norepinephrine transporter 北京雷鸟科技有限公司 2023-09-12 CN claimed
US-20230272006-A1 PEPTIDOMIMETICS AND METHOD OF SYNTHESIS THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-08-31 US claimed
US-20230100243-A1 PEPTIDOMIMETICS AND METHOD OF SYNTHESIS THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-03-30 US claimed
EP-3911372-B1 COMPOUND TARGETING NOREPINEPHRINE TRANSPORTER GUANGZHOU MIPHERE MEDICAL TECH CO LTD (CN) 2022-11-30 EP claimed
US-6344466-B2 ANTITHROMBOTIC ACTIVITY, USE IN INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, ANTICOAGULANTS 3-DIMENSIONAL PHARMACEUTICALS INC. 2002-02-05 US claimed
US-6344484-B1 TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-02-05 US claimed
US-20010037039-A1 Aminoguanidines and alkoxyguanidines as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-11-01 US claimed
US-20010031870-A1 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors SOLL RICHARD M (US) 2001-10-18 US claimed
US-6235778-B1 ANTICOAGULANTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-05-22 US claimed
EP-1070049-A1 BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-01-24 EP claimed
EP-1012165-A1 PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N- 1- 3- (AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE Aventis Pharmaceuticals Inc. (US) 2000-06-28 EP claimed
WO-1999051571-A1 BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-10-14 WO claimed
US-5739354-A ONE-STEP GUANYLATION OF 9,6-DIAMINO-5-HYDROXY-4,4-DIFLUORONONANE OR SALT; SIMPLIFICATION, HIGH YIELD END PRODUCT HOECHST MARION ROUSSEL, INC. (US) 1998-04-14 US claimed
WO-1997035874-A1 PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N-[1-[3-[(AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE HOECHST MARION ROUSSEL, INC. (US) 1997-10-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230100243-A1 PEPTIDOMIMETICS AND METHOD OF SYNTHESIS THEREOF GMPS, PAM, SRM KMT2A 3273/4885NFKB1 2460/4885NFKB2 3537/4885
US-12285501-B2 Compound targeting norepinephrine transporter SLC6A2, SLC18A2, SLC6A3 KMT2A 2778/4885NFKB1 3578/4885NFKB2 3618/4885
US-20010037039-A1 Aminoguanidines and alkoxyguanidines as protease inhibitors F9, PLG, MMP9 KMT2A 2438/4885NFKB1 3735/4885NFKB2 4068/4885
US-20230272006-A1 PEPTIDOMIMETICS AND METHOD OF SYNTHESIS THEREOF GMPS, PAM, SRM KMT2A 3273/4885NFKB1 2460/4885NFKB2 3537/4885
US-20010031870-A1 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors PLG, F9, TFPI KMT2A 994/4885NFKB1 4154/4885NFKB2 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.